In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

In a decision signed Monday, North Carolina federal judge Kenneth Bell granted Merck’s motion to dismiss the claims of ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Merck (MRK) announced the presentation of “positive” results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug ...

U.S. District Judge Kenneth Bell, who is overseeing the Gardasil multidistrict litigation in the Western District of North Carolina, sided with Merck on its implied preemption defense, granting ...

Merck plans to begin submitting applications ... to decrease in total lymphocyte and/or CD4 counts. In this open-label study, drug-related AEs were more commonly reported with DOR/ISL (n=44 ...

On Tuesday, Merck & Co (NYSE: MRK) Inc. emerged victorious in a significant legal dispute concerning its Gardasil vaccine, which is designed to prevent cervical and other serious cancers. U.S.

Merck KGaA fought for years to get the drug approved after rejection by the ... risk of cancer and birth defects, as well as a label that only supports second-line use of the drug.